Terumo's busy year

The Nikkei Asian Review has reported that Terumo is expanding its overseas presence in order to broaden its technical know-how and grow sales. The Japanese healthcare company is said to be looking to grow its net sales of US$5.2 billion per year through strategic acquisitions and partnerships. Certainly, the company has been very active with foreign acquisitions and collaborations throughout this year. Much of this activity revolves around the company’s Cardiac and Vascular Area and Blood Management businesses.

In its most recently reported move, Terumo is said to have offered up to US$1.47 billion to buy a portion of Abbott Laboratory’s cardiovascular business and “other operations” which may be up for sale. Few other details are available.

Commencing in January this year, Terumo announced the expansion of a strategic alliance with Quirem Medical B.V., a commercial stage Dutch medical technology company that focuses on radioembolisation. Terumo received exclusive global distribution rights for the liver cancer microsphere solutions developed by Quirem Medical and also obtained a buy-out option. Financial details were not disclosed.

In June, Terumo acquired US-based Sequent Medical for US$380 million. Sequent Medical’s brain aneurysm embolisation device has already received the CE Mark in Europe but is yet to be approved in the United States.

In September, Terumo entered a multicountry partnership with US-based CytoSorbents to commercialise Cytosorbent’s blood purification absorber for critically ill and cardiac surgery patients. Terumo will have exclusive distribution rights in France, Sweden, Denmark, Norway, Finland, and Iceland. Financial details of the deal were not disclosed.

Last week, Terumo announced a collaboration with US-based Cognate BioServices to support the development of cell and immunotherapy products. Cognate is a leader in cGMP and provides regulatory support to companies and institutions engaged in the development of regenerative medicine and cell-based products and therapies.

Finally, also last month, Terumo announced that it would inject up to US$300 million, to be phased in over the next eighteen months, in a newly-set up Singapore-based subsidiary, Terumo Capital Management Pte. Ltd. Terumo’s operations in the Asian region (with the exception of China and Japan) are managed by Terumo Asia Holdings Pte. Ltd., which is based in Singapore.

http://asia.nikkei.com/Business/Deals/Japan-s-Terumo-making-play-for-US-medical-device-business

http://www.meddeviceonline.com/doc/japan-s-terumo-makes-b-offer-for-abbott-s-cardiovascular-biz-0001

http://www.terumo.com/about/pressrelease/2016/20160128.html

http://www.prweb.com/releases/2016/10/prweb13726600.htm

http://www.fiercebiotech.com/medica...ents-to-commercialize-blood-purification-tech

https://www.terumo.co.jp/pressrelease/pdf/111.pdf